Mega Millions jackpot reaches $489M ahead of Thanksgiving: When's the next drawing?Yin's collaboration with the talented cast and crew of "Mistaken Identity 3" promises to deliver a cinematic experience that is both thrilling and emotionally resonant. His ability to connect with audiences on a profound level through his performances makes him a perfect fit for the complex and engaging world of the "Mistaken Identity" series.The recent incident of a budget day trip for seniors, promising a full day of activities for only 9.9 yuan, has once again highlighted the dangers of falling into low-cost traps. In the morning, the elderly participants were promised a day of learning and entertainment, but by the afternoon, they found themselves stranded on the side of the road, abandoned by the organizers. This shocking turn of events serves as a stark reminder of the risks associated with seemingly irresistible deals and the importance of being vigilant when it comes to accepting such offers.
In conclusion, the prevalence of public transport sexual harassment is a serious issue that requires immediate attention and concerted efforts to address. By establishing clearer definitions, implementing training programs, enhancing reporting mechanisms, and fostering public awareness, we can work together to prevent and respond to instances of sexual harassment on public transport effectively. Let us strive towards building a public transport system that is safe, respectful, and welcoming for everyone.As we reflect on the absence of Messi and Ronaldo from the annual best XI, it is clear that we are witnessing a changing of the guard in the world of football. While these two icons will always be remembered as two of the greatest players to have ever graced the game, it is time for new stars to shine and carry the torch forward. The emergence of a new generation of talent signals the dawn of a new era in football, one that is sure to be filled with excitement, drama, and unforgettable moments on the pitch.Godzilla and King Kong surely weren't born big. They began small and grew over time to their gargantuan sizes even if the movies don't tell their childhood stories. Likewise, huge companies of today were once much smaller (unless perhaps they were spin-offs). Investors who spotted them early had opportunities to make fortunes. Are You Missing The Morning Scoop? Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Can you still find such monsters in the making? Three Motley Fool contributors think so. Here's why they think biotech stocks CRISPR Therapeutics (NASDAQ: CRSP) , Summit Therapeutics (NASDAQ: SMMT) , and Viking Therapeutics (NASDAQ: VKTX) could become much larger. An underrated stock with two approvals under its belt David Jagielski (CRISPR Therapeutics): If you're looking for stocks with mammoth upside, you might be tempted to look for risky stocks that don't have any approved drugs or treatments yet. But with CRISPR Therapeutics, you already have a stock that has an approved treatment -- it simply isn't far along in its rollout. In December 2023, regulators approved Casgevy, which is a gene-editing therapy the company has been developing with Vertex Pharmaceuticals . It was approved as a treatment for sickle cell disease for patients 12 years and older. Then, a month later, it was also approved to treat people with transfusion-dependent beta-thalassemia (for the same age group). Casgevy can be a game changer for patients with these rare blood disorders as it is a one-time functional cure. CRISPR will share in the profits with Vertex on Casgevy (collecting 40% of them), which could potentially help the company get to profitability. Currently, its operations are well funded with CRISPR reporting more than $1.9 billion in cash and marketable securities as of the end of September. For a business that has burned through $92.7 million in cash over the past nine months, that can provide it with a lot of runway and time to grow its operations and work on other treatments in its pipeline. At a modest market cap of just $4 billion, there's a lot of room for CRISPR to get a whole lot more valuable in the future as it scales its operations and Casgevy starts to generate revenue. Buying the healthcare stock now can be a great move for long-term investors. Already showing monster potential Keith Speights (Summit Therapeutics): It's practically unheard of for a company with no product on the market to have a market cap of $14 billion. But Summit Therapeutics is no ordinary company. The drugmaker in-licensed cancer immunotherapy ivonescimab in January 2023. That has turned out to be a brilliant move in retrospect. Earlier this year, Akeso (which originally developed ivonescimab) announced the drug beat Merck 's blockbuster immunotherapy Keytruda in a head-to-head late-stage study targeting non-small cell lung cancer (NSCLC). How big of a deal was this news? Consider that Keytruda was the world's best-selling drug last year, raking in sales of around $25 billion. Summit owns the commercial rights in the U.S., Canada, and Europe of a cancer immunotherapy that could be even more powerful than Keytruda. Granted, Summit can't ride on the clinical success achieved by Akeso. The company must conduct its own clinical studies to hopefully win approval for ivonescimab in the U.S. and elsewhere. However, that's exactly what it's doing with initial results expected from a late-stage study of the immunotherapy as a second-line treatment for NSCLC in mid-2025. Summit is also evaluating ivonescimab in another late-stage trial as a first-line treatment for NSCLC. Wall Street's consensus is that Summit's share price could soar more than 40% over the next 12 months. I'm not sure if this price target will be achieved, but it wouldn't surprise me if that's an overly pessimistic goal assuming the company announces positive clinical results next year. Summit Therapeutics is already showing monster potential. I suspect it will fulfill that potential if ivonescimab wins U.S. regulatory approval. You can still get in on the ground floor Prosper Junior Bakiny (Viking Therapeutics): Weight-loss management is the hottest therapeutic area in the pharmaceutical industry right now. Although the companies dominating the field are the usual suspects, a notable mid-cap biotech called Viking Therapeutics is looking to make waves in this market. Viking's lead anti-obesity candidate, VK2735, reported excellent results in phase 2 studies. It might still be a few years until VK2735 earns regulatory approval, but Viking Therapeutics is not a one-trick pony. The company is working on an oral version of VK2735 -- something many patients would choose over the weekly injections the original formulation comes with. Furthermore, Viking Therapeutics has another promising weight-loss candidate in preclinical studies . And I have yet to mention the drugmaker's VK2809, an investigational medicine for metabolic dysfunction-associated steatohepatitis -- a liver disease with obesity as a risk factor -- and Viking's VK0214, an investigational therapy for a rare nervous system disease called X-linked adrenoleukodystrophy. Many smaller drugmakers tend to hyperfocus on a single medicine, a strategy that allows them to avoid spreading their resources thin. Viking Therapeutics, though, is taking a different approach. The company is showing signs of one of the most critical factors successful biotechs need: innovation. There are still risks involved here. Viking's late-stage studies for VK2735 could flop. However, the company is looking increasingly attractive. In a decade, it could join the ranks of highly successful drugmakers. It's not too late to get in on the ground floor. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and CRISPR Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $898,809 !* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of November 18, 2024 David Jagielski has no position in any of the stocks mentioned. Keith Speights has positions in Vertex Pharmaceuticals. Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics, Merck, Summit Therapeutics, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy . 3 Monster Stocks in the Making was originally published by The Motley Fool
Title: "Controversy Erupts as Elderly Woman Sets Mountain Ablaze While Collecting Plastic Bottles: The Incineration of Nature for the Sake of Recycling"The modus operandi of DroidBot involves leveraging social engineering techniques to lure unsuspecting users into downloading the fake apps from unofficial sources. These counterfeit applications bear striking similarities to the authentic banking apps, making it difficult for users to discern the difference. Once installed on a device, DroidBot begins its nefarious activities, ranging from stealing login credentials and personal data to conducting fraudulent transactions without the user's knowledge.NYPD Community Response Team lacks defined mission, transparency, report says
While it may not seem like the most romantic option, the useful gift of money is the most desired Christmas present in the United States this year. As Statista's Anna Fleck reports, according to the latest data from Statista’s Consumer Insights , when asked which gifts U.S. adults would personally most like to receive, 45 percent of women and 34 percent of men said cash or bank transfers. For both groups, clothing, textiles or shoes came in second position, followed by vouchers in third . Respondents could choose multiple options in the poll. You will find more infographics at Statista While there is a fair bit of overlap when looking at a breakdown of the data for men and women, some slight differences do emerge. For example, cosmetics, perfume and body care ranked as the fourth most popular option among women (27 percent), while it came in 13th place out of the possible 20 options for men (12 percent). Rounding off the top ten for men were board games/toys/dolls (15 percent) as well as event tickets (14 percent) and for women computers/computer accessories (17 percent) followed by board games/toys/dolls (15 percent). Out of the polled options, "decoration articles" were among the lowest scoring gifts, only desired by 10 percent of female respondents and 6 percent of men.
The collaborative skin, officially named "Iron Deflection," showcases Genji sporting a sleek and futuristic armor inspired by the iconic Iron Man suit. The color palette combines Genji's signature green hues with Iron Man's trademark red and gold, creating a visually striking design that pays homage to both characters in a seamless fusion of styles.
